Male Stress Urinary Incontinence Market Size & Share 2026-2035

Male Stress Urinary Incontinence Market Size

The global male stress urinary incontinence market was valued at USD 834.7 million in 2025. The market is expected to grow from USD 884 million in 2026 to USD 1.6 billion in 2035, at a CAGR of 6.7% during the forecast period, according to the latest report published by Global Market Insights Inc.

Growing incidence of prostate cancer, rising prevalence of male stress urinary incontinence, and technological advancements in devices and surgical techniques, among other factors, are driving the market growth.

Expansion of urology specialty clinics, development of next‑generation AUS designs, and the rising cases of post‑prostatectomy incontinence are expected to propel the industry demand. Boston Scientific, Becton, Dickinson and Company, Coloplast, Teleflex, and Zephyr Surgical Implants (ZSI) are among the leading players operating in the market. These players mainly focus on product innovation, geographic expansion, adoption of the latest technologies in devices, and collaboration with local or regional healthcare providers, among others.
 

The market has increased from USD 721.1 million in 2022 and reached USD 790.8 million in 2024, with the historic growth rate of 4.7%. The latest advancements in male incontinence operations, including new slings and next-generation artificial urinary sphincters, are changing the treatments provided to people with incontinence. Newer sling types have utilized stronger materials, adjustable designs to provide a better fit, and developed more effective retro-pubic and trans-obturator operating techniques, all of which lead to improved support of the urethra and increased continence rates among men. In addition, improvements in artificial urinary sphincters have increased their robustness and mechanical reliability and have added antibiotic-impregnated components, resulting in fewer complications and, therefore, longer use of the device. This has collectively led to an increase in the popularity of surgical interventions for SUI and overall market growth in this segment of the healthcare market.
 

Prostate cancer remains one of the most common malignancies in men, and its rising incidence is directly linked to greater SUI prevalence because urinary leakage is a frequent side effect of prostate cancer treatments. For instance, according to the data reported by the Centers for Disease Control and Prevention (CDC), in 2022, around 255 thousand new prostate cancers were reported in the U.S. A significant number of men experience incontinence after having a radical prostatectomy, and multiple studies show high rates in the year post-operatively.
 

Further, as the number of prostate cancer diagnoses continues to increase around the globe, particularly with the growing aging population, it may result in a surge in men suffering from incontinence as a result of the treatment for prostate cancer. There is now a greater demand for both surgical and conservative management of SUI since it is recognized as one of the major complications following prostate cancer treatment.
 

The market includes medical devices designed to treat involuntary urine leakage caused by physical activities such as coughing, lifting, or exercising. It primarily covers products like artificial urinary sphincters and male slings. The market focuses on improving patient quality of life through effective continence restoration. It involves manufacturers, healthcare providers, and specialized urology centers delivering diagnostic and therapeutic interventions for male SUI.

Male Stress Urinary Incontinence Market Trends

A shift toward minimally invasive and outpatient procedures, innovation in implantable continence technologies, urology-focused expansion through acquisitions and product development, and customer-centric innovation and technology adoption are among the key trends shaping the market growth.
 

• The rise in volume of shifting continence-related surgical procedures to outpatient or minimally invasive care settings, with innovative technology such as adjustable balloon systems and simplified sphincters, has notably reduced the barriers to treatment for patients with SUI. This development is encouraging increased adoption of SUI therapy and is consistent with the general trend towards improving efficiency across the healthcare system and facilitating faster recovery of patients following treatment.
   
• Additionally, various leading industry players, such as Boston Scientific, are committed to growing their high-growth surgical and urology businesses through a combination of acquisitions, innovative device platforms, scalable manufacturing systems, and continuous product development. This focus on technology-driven growth is creating significant competition in these sectors. Thus, the enhanced range of therapeutic options has increased the likelihood that clinicians may utilize these products more widely, resulting in a positive effect on the growth in adjacent SUI treatment.
   
• Further, companies are focusing on developing products based on the needs of their customers by incorporating new technologies, such as AI-enabled platforms, to enhance the user experience, increase accessibility, and ultimately improve standards of care for consumers. This trend has increased the speed at which companies are modernizing their products and is creating growing demand for advanced incontinence products.
   
• Moreover, advanced surgical solutions, including specifically designed reservoir-free sphincters (e.g., ZSI 375), may allow surgeons to perform surgery more easily with fewer surgical complications. In addition to improving patient outcomes, these advancements may also encourage urologists to adopt new technologies to position themselves competitively against different implantable SUI devices.
   

Male Stress Urinary Incontinence Market Analysis

In 2022, the market was valued at USD 721.1 million and grew to USD 753.8 million in 2023, reaching USD 790.8 million by 2024. Rising focus on quality‑of‑life improvement in urology care and growing elderly male population are among the key variables contributing to industry growth.
 

Based on product type, the global male stress urinary incontinence market is segmented into surgical, and non-surgical. The surgical segment accounted for a leading share of 66.2% in 2025. Growth of outpatient/ASC‑based SUI interventions is a key factor fueling the segmental growth. The segment is expected to reach USD 1.1 billion by 2035, growing at a CAGR of 6.9% during the forecast period.
 

• The surgical component of treating moderate to severe male stress urinary incontinence is based upon the Artificial Urinary Sphincter (AUS), which is considered to be the gold standard. The AUS has a proven track record of high continence rates and reliable long-term data and is promoted by clinical professionals and practice guidelines based upon its use.
   
• Additionally, male sling devices are another significant treatment modality for mild to moderate SUI. They provide symptom relief when patients have some preserved urethral function. Sling placement has consistently demonstrated excellent post-surgical outcomes; therefore, they are accepted by the urologic community as an option for individuals who do not require an AUS.
   
• Further, adjustable balloon implants, such as ProACT, use a less invasive technique than AUS but provide adjustability postoperatively. The adjustable nature of these implants appeals to the patients who prefer less complex surgical procedures.
   
• The non-surgical segment was valued at USD 282.1 million in 2025. It contains mainly condom catheters and penile clamps. Generally, patients who are not eligible or do not want to go for surgical intervention use these items. The condom catheter collects urine from the outside of the body and provides a discreet way of managing urine while still allowing the person to move freely and maintain an acceptable quality of life after prostate surgery.
   
• Furthermore, condoms and clamps are frequently used as temporary devices before or after surgery. Their ease of use and non-invasive delivery method make them relevant options for managing male SUI.

Based on end use, the male stress urinary incontinence market is segmented into hospitals, ambulatory surgical centers, urology clinics and other end users. The hospitals segment accounted for the leading market share of 48.6% in 2025.
 

• The current SUI treatment landscape is heavily reliant upon hospitals, as they are the primary institutions performing AUS placement, which involves trained surgeons and an established surgical environment. AUS procedures performed via outpatient or short-stay surgical methods are often done at such hospital systems that have been trained in the procedures and also have established urological programs.
   
• Many hospitals are responsible for managing more complex cases of severe SUI following prostate treatment and have a multidisciplinary approach to patient management. In addition, they provide services related to diagnostic evaluation, urodynamics, cystoscopy, and postoperative instruction on the use of implanted devices. Thus, hospitals serve as centralized resources for advanced treatment of SUI, especially during cases of moderate to severe SUI requiring the use of implantable technologies.
   
• The ambulatory surgical centers segment is anticipated to record higher growth with a CAGR of 7.3% over the forecast period. ASCs increasingly perform minimally invasive SUI procedures, supported by technologies like adjustable balloon implants that are implanted through short, outpatient‑friendly interventions.
   
• The shift toward outpatient surgery has also been witnessed in many AUS cases, which reduces patient recovery time and procedural costs, boosting ASC utilization.

North America Male Stress Urinary Incontinence Market

North America market accounted for leading share of 46.6% in 2025 in the market and is anticipated to show considerable growth over the forecast period.
 

• The U.S. market was valued at USD 312.8 million and USD 326.4 million in 2022 and 2023, respectively. In 2025 the market size was valued at USD 359.9 million from USD 341.7 million in 2024. Integration of digital tools for follow‑up/monitoring in the country is projected to fuel the market growth.
   

• The North American men's SUI market is consistently growing, due to the high level of awareness of men's urinary incontinence following prostate treatment and a large adoption of modern solutions for urinary incontinence.
   
• Additionally, the urology industry is well established in North America, which helps to ensure early diagnosis occurs, follow-up with timely referrals takes place, and surgical and non-surgical options are available to the patient.
   
• In addition to the benefits of the well-established North American urology ecosystem, the advanced healthcare infrastructure helps to support minimally invasive procedures to treat men's urinary incontinence, outpatient treatment of men's urinary incontinence, and continuing device follow-up through to the end of the patient's life.
   
• Moreover, growing conversations around men’s health and rising willingness to discuss urinary issues are further reducing stigma, enhancing treatment uptake, broadening the overall demand for SUI treatment in North America.
   

Europe Male Stress Urinary Incontinence Market

Europe accounted for a significant share of the global market and was valued at USD 200 million in 2025.

• In Europe, there is a well-established male stress urinary incontinence (SUI) market due to strong clinical standards and practice, a significant focus on the use of evidence-based practices, and a growing user base of continence therapies integrated into the national healthcare systems.
   
• Urology departments have established structured pathways that provide clinicians with tools to diagnose SUI in a timely fashion, particularly in patients who have been treated for prostate disease and are at risk for developing SUI from prostate surgical treatment.
   
• Further, the aging population of Europe, along with the high rate of prostate disease, allows continued clinical demand for continence therapy. In addition, there are also a number of patient support groups and continence foundations in Europe that create awareness about SUI and promote acceptance of treatment for SUI.
   

Asia Pacific Male Stress Urinary Incontinence Market

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 166.5 million in 2025.

• There is an increase in demand for male SUI care in the Asia Pacific region due to a rise in prostate treatment and an improving understanding of continence (leakage) by men through enhanced consumer awareness and increased access to health care systems.
   
• Additionally, the rise in the number of men being evaluated for post-surgical or age-related incontinence as diagnostic tools become more widely available to them has led to an increased need for SUI treatment, resulting in a number of options available to treat male incontinence.
   
• Large urban populations, along with greater access to tiered specialty health care, are leading to widespread adoption of surgical and non-surgical treatment options available to men with incontinence issues.
   
• Further, urology associations and hospital systems have initiated several educational programs to facilitate treatment, reduce stigma related to male pelvic health issues, which prevented men from receiving the treatment.
   

Latin America Male Stress Urinary Incontinence Market

The Latin American market is anticipated to exhibit remarkable growth during the analysis period.
 

• Latin America is experiencing gradual growth in male SUI treatment as awareness increases and access to specialized urology services improves. Urban centers, in particular, are expanding their capabilities for continence diagnostics and interventions, including both device‑based and conservative treatment options.
   
• Many men undergoing prostate surgery are now more frequently evaluated for postoperative incontinence, leading to higher identification rates.
   
• Additionally, public and private healthcare institutions are also investing in modern technologies and clinical training, helping broaden the availability of advanced SUI therapies. 
   

Middle East and Africa Male Stress Urinary Incontinence Market

The Middle East and Africa market is expected to experience substantial growth over the analysis timeframe.
 

• The MEA region shows progressive development in male stress urinary incontinence management as healthcare systems expand specialized urology departments and invest in modern surgical capabilities.
   
• Additionally, countries in the Gulf region continue to advance their medical infrastructure, enabling greater access to continence interventions, including minimally invasive options.
   
• In other parts of the region, awareness of male incontinence is gradually increasing through hospital‑based education programs and clinician‑led outreach. In addition, efforts to reduce stigma surrounding urinary disorders are helping improve patient willingness to seek evaluation for male SUI treatment services.
   

Male Stress Urinary Incontinence Market Share

The global male stress urinary incontinence (SUI) device landscape is consolidated in nature with a combination of diversified med-tech businesses and several specialist implant manufacturers, with competition based on innovation, portfolio differentiation, and surgical technology leadership.
 

Additionally, Boston Scientific, through its innovation-driven approach, strategic acquisition, and increased funding for global scalability, may further improve its competitiveness for urology and surgical technologies. This is supported by ongoing product development and operational execution of all products in their wide portfolio across continents.
 

Further, through its customer-centric product development and Impact4 strategic plan (which focuses on efficiency, technology adoption, and sustainable leadership), Coloplast has established a significant competitive advantage in the area of continence care, covering surgical and non-surgical solutions. Similarly, Zephyr Surgical Implants is a key competitor within the implantable incontinence solutions space by offering less invasive implantations with an adjustable, simplified approach to artificial urinary sphincters, putting it at a notable advantage relative to traditionally designed multi-component systems.
 

Furthermore, other key players in the market, such as Becton, Dickinson and Company, Teleflex, Rigicon, and Promedon, among others, are also playing an important role by investing significantly in product innovation and geographic expansion with a focus on improving their industry presence.
 

Male Stress Urinary Incontinence Market Companies

A few of the prominent players operating in the global male stress urinary incontinence industry include:

• A.M.I. GmbH
• Becton, Dickinson and Company
• Boston Scientific
• CL Medical
• Coloplast
• Neomedic
• Promedon
• Rigicon, Inc.
• Teleflex
• Zephyr Surgical Implants (ZSI)

• Boston Scientific

Boston Scientific pursues growth through innovation, strategic acquisitions (e.g., Axonics), AI‑enhanced technologies, and global expansion, focusing on high‑growth therapeutic areas to strengthen market leadership and operational scale.
 

• Becton, Dickinson and Company

BD is executing its BD 2025 strategy, reshaping into a focused MedTech leader via portfolio separation, innovation investment, connected‑device expansion, and operational excellence to drive long‑term growth and value.
 

• Coloplast

Coloplast’s Impact4 strategy emphasizes customer‑centric innovation, efficiency gains, technology adoption (including AI), and sustainable growth, strengthening its leadership across chronic care and intimate healthcare markets.
 

Male Stress Urinary Incontinence Industry News

• In January 2026, Coloplast signed a definitive merger agreement with U.S.-based MedTech firm Uromedica. Uromedica offers ProACT, the adjustable continence balloons, in the U.S., Europe, and other markets. This acquisition will strengthen the company’s portfolio and presence in the male incontinence segment of urology.
   
• In July 2025, UroMems, a global company developing innovative mechatronics technology to treat stress urinary incontinence (SUI), received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) and French National Agency for the Safety of Medicines and Health Products (ANSM) clearance. This clearance may enable the company to begin a first-of-its-kind pivotal clinical trial of the UroActive smart implant to treat stress urinary incontinence (SUI) in men.
   

The global male stress urinary incontinence market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Surgical
  • Artificial Urinary Sphincter (AUS)
  • Male slings
  • Adjustable continence balloons
• Non-Surgical
  • Condom catheters   
  • Penile clamps

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Urology clinics
• Other end users
   

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE